Inotuzumab (Besponsa) has been recommended for PBS subsidy for patients with acute lymphocytic leukaemia (ALL) by the Pharmaceutical Benefits Advisory Committee (PBAC). The new PBS listing will be for the treatment of relapsed or refractory CD22 positive B-cell precursor ALL. At its November meeting the PBAC concluded that sequential use of inotuzumab and blinatumomab (in ...
Leukaemia and lymphoma drugs get PBS listing approval
By Michael Woodhead
14 Jan 2019